These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients. Peer FC; Miller A; Pavli P; Subramaniam K Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199 [TBL] [Abstract][Full Text] [Related]
5. Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab. Shimokata M; Namiki T; Tokoro S; Ugajin T; Miura K; Yokozeki H J Dermatol; 2018 Dec; 45(12):e331-e333. PubMed ID: 29855072 [No Abstract] [Full Text] [Related]
6. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161 [TBL] [Abstract][Full Text] [Related]
7. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Melo FJ; Magina S Int J Dermatol; 2018 Dec; 57(12):1521-1532. PubMed ID: 30028008 [TBL] [Abstract][Full Text] [Related]
8. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059 [TBL] [Abstract][Full Text] [Related]
9. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978 [TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse reaction to infliximab: report of psoriasis developing in 3 patients. Severs GA; Lawlor TH; Purcell SM; Adler DJ; Thompson R Cutis; 2007 Sep; 80(3):231-7. PubMed ID: 17956013 [TBL] [Abstract][Full Text] [Related]
11. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804 [TBL] [Abstract][Full Text] [Related]
12. Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study. Coutzac C; Chapuis J; Poullenot F; Chabrun E; Capdepont M; Blanco P; Laharie D J Crohns Colitis; 2015 Nov; 9(11):982-7. PubMed ID: 26351388 [TBL] [Abstract][Full Text] [Related]
13. Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors. Eickstaedt J; Paller AS; Lund E; Murphrey M; Brandling-Bennett H; Maurano M; Fernandez Faith E; Holland KE; Ibler E; Liang MG; Todd PS; Siegfried E; Igelman S; Cordoro KM; Tollefson MM JAMA Dermatol; 2023 Jun; 159(6):637-642. PubMed ID: 37043214 [TBL] [Abstract][Full Text] [Related]
14. Anti-TNFα antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease: an Irish Cohort Study. Kirthi Jeyarajah S; Tobin AM; Hussey M; Scaldaferri F; McNamara D QJM; 2017 Jun; 110(6):379-382. PubMed ID: 28069913 [TBL] [Abstract][Full Text] [Related]
15. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906 [TBL] [Abstract][Full Text] [Related]
16. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Hellström AE; Färkkilä M; Kolho KL Scand J Gastroenterol; 2016; 51(5):563-71. PubMed ID: 26728295 [TBL] [Abstract][Full Text] [Related]
17. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Collamer AN; Battafarano DF Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412 [TBL] [Abstract][Full Text] [Related]
18. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease. George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749 [TBL] [Abstract][Full Text] [Related]
19. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. Denadai R; Teixeira FV; Steinwurz F; Romiti R; Saad-Hossne R J Crohns Colitis; 2013 Aug; 7(7):517-24. PubMed ID: 22960136 [TBL] [Abstract][Full Text] [Related]
20. Six Cases of Lung Injury Following Anti-tumour Necrosis Factor Therapy for Inflammatory Bowel Disease. Lee HS; Jo KW; Shim TS; Song JW; Lee HJ; Hwang SW; Park SH; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Kim JH; Yang SK J Crohns Colitis; 2015 Nov; 9(11):1053-7. PubMed ID: 26221002 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]